Business Wire

CYNORA Announces Availability of Industry’s First Device Test Kits for TADF Deep Green Emitters for Next-Generation OLED Displays

20.1.2021 09:00:00 EET | Business Wire | Press release

Share

Marking a new innovation trajectory for the OLED industry, CYNORA today announced that device test kits for its Thermally Activated Delayed Fluorescence (TADF)-based Deep Green emitter for next-generation OLED displays are now available to customers. The development is an industry-first milestone for TADF technology, and validates CYNORA’s roadmap commitment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119006159/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

cyUltimateGreen™ - CYNORA's TADF Deep Green Emitter Device Test Kit (Photo: Dr. Harald Flügge, CYNORA)

Known as the cyUltimateGreen™, the product delivers efficiency of more than 20 percent, which meets current industry specifications of 150cd/A in top emission devices. It demonstrates lifetime of 400h LT95@15mA, and color point and spectra that match today’s DCI-P3 standard. In addition, the product shows compatibility with BT2020, a color standard that requires greater color purity than DCI-P3, and one that will significantly enlarge the color depth.

The milestone delivers a materials technology breakthrough that will help display manufacturers unleash the full efficiency potential of new-generation OLEDs and catalyze game-changing OLED products. It starts with TADF Deep Green and will soon include a TADF Deep Blue solution.

The cyUltimateGreen Emitter: A “Brightness” Booster for Next-Generation OLEDs

Within the OLED stack is the emissive layer. This is where the light is made. Within the layer are Red, Green and Blue pixels. By combining all three, the full color gamut is rendered in the display. The Green pixel influences brightness. It accounts for as much as 25 percent of the OLED stack costs.

CYNORA’s CEO, Adam Kablanian, commented: “We set out to innovate a differentiated new technology that would enable display leaders to leapfrog beyond legacy emitter solutions for next-generation OLEDs. We believed that TADF was the most promising approach. We knew that with the right blend of advanced technologies and chemistry expertise, the breakthrough was achievable. Our talented team has confirmed the commercial capability of the TADF emitter technology, which has the ability to offer customers substantial savings. The kits are now ready for customer testing and verification.”

GEM: CYNORA’s Materials Discovery Advantage

Behind the cyUltimateGreen product is CYNORA’s Generative Exploration Model (GEM). GEM is the materials discovery engine pioneered by CYNORA to identify with extreme precision the most relevant and useful molecules, and related combinations, from an infinite source of chemical molecules.

GEM combines two key elements: artificial intelligence (AI) and the brainpower of CYNORA’s chemists. While AI offers immense computational capabilities, there can be prediction errors and other uncertainties that diminish the output of useful data for specialized applications. GEM supercharges AI for OLED materials discovery by pairing its computing power with the materials expertise and OLED device knowledge of CYNORA’s chemists to identify molecules with high potential. From there, a scoring system predicts how closely the molecule conforms to must-have parameters, as well as its usefulness for the target purpose – in this case, high-efficiency emitter materials.

GEM strengthened CYNORA’s discovery and synthesis capabilities, and fast-tracked completion of the cyUltimateGreen product, said CTO, Dr. Jan Richter. “Given that the universe of chemical molecules is infinite, identifying the most relevant molecules is exceedingly tough,” he said. “While AI gives us a powerful discovery acceleration tool, our imperative isn’t just to find molecules that are a theoretical fit; they must also be chemically synthesizable. That’s where CYNORA’s chemistry expertise provides the value add.”

The expertise extends to CYNORA technologists’ deep knowledge of the full OLED device. This helped the company engineer the cyUltimateGreen to meet mass-production requirements, without requiring display leaders to make expensive alterations to their manufacturing lines. Essential details like matching evaporation temperatures to meet current device architectures, and aligning material parameters (like energy levels), were part of the calculations. To further reduce cost, integration factors were also considered, like how to manufacture the product within existing hardware and process frameworks without requiring extra evaporation chambers.

Richter added: “TADF technology is igniting a new innovation trajectory for OLED emitter materials. We’re excited to lead with our cyUltimateGreen product.”

For information on CYNORA GmbH, please visit www.cynora.com

cyUltimateGreen is a trademark of CYNORA GmbH

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Company Contact
Joanna Folberth; email: folberth@cynora.com

Agency Contact
Genuity Communications for CYNORA; email: cynora@genuitypr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release

Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release

The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye